Vídeos de imunoterapia
551 vídeos de imunoterapia de sociedades, congressos e centros de oncologia (2 em português). Lista atualizada em 20/11/2026; abaixo, os mais recentes.
Assistir ao canal Imunoterapia no OncoTV
Could immunotherapy plus an ADC replace the standard of care in NSCLC?VJOncology · 19/11/2026 · 1:12 · apoio da indústria
Durvalumab + Enfortumab vedotin FDA Approval for Muscle Invasive Bladder Cancer (MIBC): VOLGAOncology Brothers · 17/11/2026 · 25:38 · apoio da indústria
Estudo KEYNOTE-B49 - Imunoterapia no Câncer de Mama Luminal | GBECAM na ESMO 2026GBECAM · 12/11/2026 · 3:30
ESMO Asia 2026 - Programme Highlights with Prof. Paolo A. AsciertoESMO · 10/11/2026 · 1:56
Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hod...ecancer · 10/11/2026 · 3:59 · apoio da indústria
Beyond the Scan: Predicting Immunotherapy Response With ctDNA in NSCLCTargeted Oncology · 03/11/2026 · 15:24 · apoio da indústria
CALR-targeted immunotherapy in myelofibrosis and ET: vaccine and antibody approachesVJHemOnc · 03/11/2026 · 3:38 · apoio da indústria
JCO at ESMO 2026: Phase 2 Neoadjuvant Cemiplimab in CSCC: Final AnalysisASCO Podcasts · 24/10/2026 · 20:46
MRD Surveillance After Immunotherapy-Based Treatment in Older AdultsASH · 20/10/2026 · 3:47
Terapia sistêmica: imunoterapia e seus efeitos colaterais - Dra. Sofia VidaurreSBOC · 02/10/2026 · 18:44
Smarter CARs: Using AI to Improve Chimeric Antigen Receptor DesignEHA · 18/08/2026 · 17:43
Drs Lee and Saxena on the Study of PD-L1 Expression in EGFR-Mutated NSCLCOncLive · 24/04/2026 · 1:58 · apoio da indústria
ElizabethJaffee AACRio26 Interview Video2 Final SidecarAACR · 20/02/2026 · 2:17
Maintenance Lurbinectedin + Atezolizumab Improves Survival Outcomes in ES-SCLC in IMforte TrialASCO · 02/06/2025 · 4:42
On the Scene with Leslie M. Randall, MDSGO · 17/03/2024 · 1:47
CITADEL: neoadjuvant sacituzumab govitecan and pembrolizumab in NSCLCVJOncology · 19/11/2026 · 4:37 · apoio da indústria
VOLGA: Durvalumab (PeriOp) + EV (3 cycles NeoAdj) is now FDA ✅ in cis-ineligible/refusing MIBC!Oncology Brothers · 15/11/2026 · 1:34 · apoio da indústria
ESMO Immuno-Oncology & Advanced Therapies Congress 2026 – Connect, Collaborate, InnovateESMO · 15/10/2026 · 1:54
Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancerecancer · 16/07/2026 · 1:56 · apoio da indústria
Can Doctors Predict Who Immunotherapy Will Work For? City of Hope Aims to Find OutTargeted Oncology · 07/08/2026 · 2:55 · apoio da indústria
Macrophage reprogramming and response to PD-1 blockade in smoldering myelomaVJHemOnc · 03/11/2026 · 1:25 · apoio da indústria
JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in MelanomaASCO Podcasts · 01/06/2026 · 10:29
Emerging Immunotherapies and Global Access in Relapsed B-ALLASH · 20/10/2026 · 6:30
Where Are We Now With Immunotherapy in Multiple Myeloma?EHA · 22/06/2026 · 22:34
Dr Zsiros on the Use of Pembrolizumab/Paclitaxel/Bevacizumab for Ovarian CancerOncLive · 13/04/2026 · 1:38 · apoio da indústria
AACR Immuno-Oncology Conference—Discovery and Innovation in Cancer Immunology: Dr. Antoni RibasAACR · 19/02/2026 · 1:56
Combination Atezolizumab + FOLFOX Improves DFS in Stage III dMMR Colon Cancer in ATOMIC TrialASCO · 01/06/2025 · 4:09
RAMPART: quality of life with adjuvant durvalumab in renal cell carcinomaVJOncology · 17/11/2026 · 1:31 · apoio da indústria
Sacituzumab +/- Pembrolizumab FDA Approval in Triple Negative Breast Cancer: ASCENT-03 / ASCENT-04Oncology Brothers · 04/07/2026 · 20:40 · apoio da indústria
ESMO Immuno-Oncology & Advanced Therapies Congress 2026 – Why Attend?ESMO · 15/10/2026 · 2:00
Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanomaecancer · 14/07/2026 · 1:50 · apoio da indústria
Dr Dulmage on IRAEs: Red Flags and ManagementTargeted Oncology · 30/04/2026 · 2:27 · apoio da indústria
Advances in precision-engineered T-cell immunotherapy for alloSCT in AML, ALL and MDSVJHemOnc · 30/10/2026 · 10:54 · apoio da indústria
JCO at ASCO 2026: Intravesical Recombinant BCG with Chemo-Immunotherapy in MIBCASCO Podcasts · 29/05/2026 · 13:09
Sequencing Immunotherapy After Relapse in B-ALLASH · 20/10/2026 · 9:23
EHA2025 Perspectives Report | Monoclonal antibodies versus cellular immunotherapyEHA · 03/09/2025 · 1:52
Dr Patel on the Rationale for Studying ADT Plus Pembrolizumab in Salivary Gland CancerOncLive · 10/04/2026 · 1:17 · apoio da indústria
Quinn Johnsen: Regaining Normal Life, Thanks to a Novel Personalized ImmunotherapyAACR · 17/09/2025 · 4:58
Durvalumab + FLOT Yields Significantly Improved EFS in Gastric/GEJ Cancer in MATTERHORN TrialASCO · 01/06/2025 · 3:33
NBTXR3 with radiotherapy and anti-PD-1 therapy in anti-PD-1-resistant melanomaVJOncology · 17/11/2026 · 1:56 · apoio da indústria